---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-231899"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:44:43.379348+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Crinetics' oral paltusotine succeeds in Phase 3 PATHFNDR-1; 83% maintain IGF-1 vs 4% on placebo

## Summary
- Paltusotine met primary endpoint: 83% maintained IGF-1 ≤1.0xULN vs 4% on placebo (p<0.0001).
- All secondary endpoints met, including GH <1.0 ng/mL (87% vs 28%, p=0.0003) and symptom diary scores.
- No serious or severe adverse events; AE frequency 80% paltusotine vs 100% placebo, fewer acromegaly-related events.
- PATHFNDR-2 (untreated patients) topline data expected Q1 2024; NDA submission planned for 2024.
- Phase 2 study in carcinoid syndrome interim results expected later 2023.

## SEC filing metadata
- accession: 0001193125-23-231899
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312523231899/0001193125-23-231899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312523231899/d657121d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-231899
- JSON: https://secwatch.observer/filing/0001193125-23-231899.json
- Plain text: https://secwatch.observer/filing/0001193125-23-231899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.